A Phase IB/II, Open Label, Multicenter Study of Selumetinib Administered Orally in Combination With Gefitinib in Patients With EGFR-mutated Non-small Cell Lung Cancer Who Have Developed Acquired Resistance of EGFR Inhibitor Treatment
Phase of Trial: Phase I/II
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Gefitinib (Primary) ; Selumetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 07 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.